Individual product determination in the new Dutch DBC system: how to make the system transparent for its users by Swiers, R & Kleijwegt, R
MEETING ABSTRACT Open Access
Individual product determination in the new
Dutch DBC system: how to make the system




From 27th Patient Classification Systems International (PCSI) Working Conference
Montreal, Canada. 19-22 October 2011
Introduction
On January 1st, 2012, the Dutch declaration system
(diagnosis treatment combination), which was intro-
duced in 2005, will be converted. The initial develop-
ment of this conversion was begun in 2007/2008. In all
phases of the conversion, Information technology has
supported and will continue to support the system (that
is, in early development, in transition, and from 2012 on
into production). In our presentation, we would like to
detail information regarding the development of this
new system and the support given its development by
information technology.
Methods
The initial developments that were part of the new DBC
(in English: “Diagnosis Treatment Combination”) system
were done in 2007. These developments were the result
of an agreement between all the authorities involved in
the Dutch system: hospitals, insurance companies, and
the government. The development was called ‘Project
DOT’, which can be roughly translated as ‘DBC’sO n
Their Way to Transparency’. DOT was to be developed
based on ICD-10 chapters and registration in the cur-
rent DBC system.
The new system would incorporate three large and
interdependent changes:
1. A new basic model, RSAD (in English: Register,
Extract, Deduce and Declare).
2. A new product structure to determine products.
3. New rules of registration to determine when to
declare.
For the second part – the product structure – DBC-
Onderhoud used the ICD-10 chapters and registration
available in the current system from the DBC Informa-
tion System (DIS) to develop decision trees. These trees
determine the products for a single period of patient
care. This new product structure consists of a number
of relevant elements.
The next step was to open the discussion to specia-
lists, and to decide whether these products were logical,
and whether they should be expanded or cut in the first
drafts. To enable a discussion between different parties,
DBC-Onderhoud needed an online tool that was able to
make the product structure transparent. This tool, called
the “care product viewer”, was built in cooperation with
Casemix, a Dutch consultancy organization. It allowed
everyone, literally, to see what was built, what had been
changed, and what needed to be changed.
Results
The discussions and iterations on the first draft resulted
in the creation of a product structure for inpatient and
outpatient hospital care which included approximately
4400 singular products in 123 product groups. These
product groups consist of decision trees. Within deci-
sion trees, conditions are checked (for example, a regis-
tered diagnosis code, or a performed certain-care
activity). In the product structure, there are almost 2500
current diagnosis codes, and more than 3000 activity
codes, that are used.
This structure can be roughly divided into three
categories:
1. Intensive, surgical products.
2. Conservative inpatient care products (diagnostics
and small treatment for inpatient care; no large surgery). * Correspondence: r.swiers@dbconderhoud.nl
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and small treatment for outpatient care; no large
surgery).
A patient is treated in the hospital and all provided
care is registered (such as diagnosis, diagnostics, outpati-
ent consultation, surgeries, patient days, and so on).
After a given period, decided by automatic registration
rules, the patient dataset is sent to a central web appli-
cation, the grouper. The grouper supports the rules of
the product structure and determines a care product.
For many people this feels like being in a black box, and
they want to see how a determination works to be able
to understand it.
As a result, an online tool was created to allow every-
one who was interested to see how a product was deter-
mined. The tool shows possible products that can be
declared and which type of care – at minimum – should
be provided to be able to declare a product. In addition,
a wide variety of underlying information about products
and product groups is made available.
Because of the possibilities of this tool, today (in 2011)
it is being used by hospitals, consultants, hospital repre-
sentatives, and insurance companies to analyze the
impact on their production of the transition to the new
system. As well, the tool will allow hospitals to analyze
their production from 2012 onward and evaluate
whether a faulty or unexpected product has been
determined.
The initial product structure will be ready for imple-
mentation in 2012. However, we know that additional
changes will be needed, and that these will lead to a
newer version of the product and changes to its struc-
ture. As well, all parties involved will need to be
informed of these changes in a timely and accurate
manner, so that they can assess them. In addition, trans-
parency will be needed regarding the changes. DBC-
Onderhoud has provided that via the online tool.
Conclusions
When the new system goes ‘live’ in 2012, we will pro-
vide Dutch hospitals with a system built from their own
registrations, and approved by all representatives
involved in Dutch healthcare. This was possible because
representatives were able collectively to decide on the
development of the system. We will also provide to
everyone interested a tool that shows, in great detail, the
products and their underlying structural information.
ICT has supported the development of this system, and
ITC will continue to support and service the product
throughout the transition period and into production.
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